Last reviewed · How we verify

NCT06835595: SAI-PD22

TMS-related Measures as Biomarker of Cognitive Impairment in PD

Recruiting now NA Last updated 22 December 2025
What this trial tests

NA trial testing Transcranial Magnetic Stimulation in Parkinson Disease in 52 participants. Currently enrolling.

Timeline
10 September 2025
Primary endpoint
1 January 2029
1 January 2029

Quick facts

Lead sponsorAzienda Sanitaria Universitaria Integrata del Trentino
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment52
Start date10 September 2025
Primary completion1 January 2029
Estimated completion1 January 2029
Sites3 locations across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Azienda Sanitaria Universitaria Integrata del Trentino

Who can join

18 and older, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of the present study is to explore the diagnostic and prognostic value of neurophysiological biomarkers obtained through paired-pulse Transcranial Magnetic Stimulation (TMS) techniques in individuals affected by Parkinson's disease (PD) with and without cognitive decline. The main questions it aims to answer are: * TMS measures of cortical excitability are able to distinguish between PD patients cognitively normal, PD-Mild Cognitive Impairment (PD-MCI) and PD-Dementia (PD-D)? * TMS measures of cortical excitability are able to predict progression of PD patient cognitive status from cognitively normal to PD-MCI and PD-D?

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Transcranial Magnetic Stimulation

Trials testing the same drug.

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

Other Azienda Sanitaria Universitaria Integrata del Trentino trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06835595.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing